Reauthorising US FDA user fees: a slow-moving train wreck?
This article was originally published in SRA
Failure by Congress to secure the timely reauthorisation of critical drug and device user fee programmes will mean trouble for the Food and Drug Administration, industry and patients, warns Steven Grossman.
You may also be interested in...
With the re-election of President Obama in the US, many people are sitting back and assuming that the Food and Drug Administration won’t change much. It doesn’t need to: Commissioner Margaret Hamburg is doing a good job; the agency is moving forward to improve food, drug and device safety; more rational and predictable review processes are being implemented; and there are at least three relatively new laws that need ongoing attention.